Ionis Pharmaceuticals Inc (NAS:IONS)
$ 35.91 -0.42 (-1.16%) Market Cap: 5.74 Bil Enterprise Value: 4.73 Bil PE Ratio: 0 PB Ratio: 8.65 GF Score: 40/100

Ionis Pharmaceuticals Inc Collaboration with AstraZeneca - Eplontersen Development and Commercialization Update Webcast Transcript

Dec 07, 2021 / 03:00PM GMT
Release Date Price: $30.57 (+11.16%)
Operator

Good morning, and welcome to Ionis' conference call to discuss the eplontersen development and commercialization update. As a reminder, this call is being recorded. At this time, I would like to turn the call over to Jennifer Capuzelo, Investor Relations to lead off the call. Please begin.

Unidentified Company Representative

Thank you, Tom. Hello, and thank you for joining us this morning for a discussion about our collaboration agreement with AstraZeneca for eplontersen. Before we begin, I encourage everyone to review the press release, Ionis issued last night, which outlines the details of this agreement.

During this call, we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors contained in our SEC filings for additional details.

Joining me on today's call are Brett Monia, Chief Executive Officer; Onaiza Cadoret-Manier, Chief Corporate Development and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot